Barclays Boosts Stryker (NYSE:SYK) Price Target to $443.00

Stryker (NYSE:SYK) had its price objective lifted by Barclays from $418.00 to $443.00 in a research report report published on Monday morning,Benzinga reports. Barclays currently has an overweight rating on the medical technology company’s stock.

A number of other brokerages have also weighed in on SYK. Robert W. Baird lifted their price objective on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Stifel Nicolaus upped their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. The Goldman Sachs Group boosted their price target on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research note on Thursday, January 30th. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Finally, Citigroup raised their price target on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $420.68.

Stryker Trading Down 1.3 %

NYSE SYK opened at $385.49 on Monday. Stryker has a one year low of $314.93 and a one year high of $406.19. The firm has a market cap of $146.96 billion, a PE ratio of 49.68, a P/E/G ratio of 2.98 and a beta of 0.96. The firm’s fifty day moving average is $377.27 and its two-hundred day moving average is $366.01. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the company posted $3.46 EPS. Analysts expect that Stryker will post 13.49 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Stryker

Hedge funds have recently modified their holdings of the stock. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Stryker during the fourth quarter worth $25,000. Dunhill Financial LLC lifted its holdings in Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Rakuten Securities Inc. boosted its position in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after buying an additional 68 shares during the last quarter. Centricity Wealth Management LLC acquired a new stake in shares of Stryker during the fourth quarter valued at about $30,000. Finally, BankPlus Trust Department acquired a new position in shares of Stryker in the fourth quarter worth about $33,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.